- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00715403
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
Extension Study to Establish Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Patients With Previous Clinical Benefit From BIBF 1120
The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in terms of incidence and intensity of Adverse Events and changes in safety laboratory parameters.
Secondary objectives are the collection of further safety data (vital signs), efficacy data and the determination of pharmacokinetic characteristics during long-term therapy with BIBF 1120.
Studieöversikt
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Bordeaux cedex, Frankrike
- 1199.16.3306A Boehringer Ingelheim Investigational Site
-
Clichy Cedex, Frankrike
- 1199.16.3311A Boehringer Ingelheim Investigational Site
-
Clichy Cedex, Frankrike
- 1199.16.3311B Boehringer Ingelheim Investigational Site
-
Paris, Frankrike
- 1199.16.3312A Boehringer Ingelheim Investigational Site
-
Paris Cedex 10, Frankrike
- 1199.16.3313A Boehringer Ingelheim Investigational Site
-
Paris Cedex 10, Frankrike
- 1199.16.3313E Boehringer Ingelheim Investigational Site
-
Paris cedex 15, Frankrike
- 1199.16.3302A Boehringer Ingelheim Investigational Site
-
-
-
-
-
Freiburg/Breisgau, Tyskland
- 1199.16.49001 Boehringer Ingelheim Investigational Site
-
Grosshansdorf, Tyskland
- 1199.16.49004 Boehringer Ingelheim Investigational Site
-
Tübingen, Tyskland
- 1199.16.49008 Boehringer Ingelheim Investigational Site
-
Wiesbaden, Tyskland
- 1199.16.49005 Boehringer Ingelheim Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female patients with advanced solid tumours who have completed a previous study with BIBF 1120. The patients should not have progression of their underlying tumour disease unless there is evidence for significant clinical benefit (e.g. symptom improvement) from treatment with BIBF 1120.
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score <= 2
- Patients must have given written informed consent (which must be consistent with ICH-GCP and local legislation)
Exclusion Criteria:
- Time elapsed from last administration of BIBF 1120 in the previous trial to start of treatment in the present trial exceeds four weeks
- Presence of drug related toxicity > grade 2 CTC from previous therapy with BIBF 1120 or presence of drug related continuous toxicity of grade 2 for seven or more consecutive days which would preclude ongoing chronic therapy with BIBF 1120
- Active ulcers (gastro-intestinal tract, skin)
- Major injuries and surgery within the past three weeks with incomplete wound healing
- Hypersensitivity to BIBF 1120 or the excipients of the trial drug
- Known secondary malignancy requiring therapy
- Active infectious disease
- Significant cardiovascular diseases (i.e. uncontrolled severe hypertension, unstable angina pectoris, history of myocardial infarction, congestive heart failure > NYHA II)
- Gastrointestinal disorders anticipated to interfere with the resorption of the study drug
- Brain metastases requiring therapy
- Absolute neutrophil count less than 1,500/mm3
- Platelet count less than 100,000/mm3
- Bilirubin greater than 1.5 mg/dl (> 26 µmol/L)
- Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
- Serum creatinine greater than 2 mg/dl (> 176 µmol/L)
- Concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug
- Chemo-, radio-, or immunotherapy within the past four weeks prior to treatment with the trial drug
- Patients who are sexually active and unwilling to use a medically acceptable method of contraception
- Pregnancy or lactation
- Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy (visit 2) or concomitantly with this trial (except for a previous study with BIBF 1120)
- Patients unable to comply with the protocol
- Active alcohol or drug abuse
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1
Tidsram: From signing the informed consent until final follow-up, up to 991 days
|
All patients who had grade 1 adverse events (AEs) as the worst grade of the AE.
Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
|
From signing the informed consent until final follow-up, up to 991 days
|
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2
Tidsram: From signing the informed consent until final follow-up, up to 991 days
|
All patients who had grade 2 adverse events (AEs) as the worst grade of the AE.
Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
|
From signing the informed consent until final follow-up, up to 991 days
|
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3
Tidsram: From signing the informed consent until final follow-up, up to 991 days
|
All patients who had grade 3 adverse events (AEs) as the worst grade of the AE.
Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
|
From signing the informed consent until final follow-up, up to 991 days
|
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4
Tidsram: From signing the informed consent until final follow-up, up to 991 days
|
All patients who had grade 4 adverse events (AEs) as the worst grade of the AE.
Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
|
From signing the informed consent until final follow-up, up to 991 days
|
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5
Tidsram: From signing the informed consent until final follow-up, up to 991 days
|
All patients who had grade 5 adverse events (AEs) as the worst grade of the AE.
Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
|
From signing the informed consent until final follow-up, up to 991 days
|
Difference From Baseline for Liver Enzymes
Tidsram: From signing the informed consent until end of treatment, up to 991 days
|
Difference from baseline (normalized value).
Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication.
The standard error is actually the Interquartile Range calculated as P75 minus P25.
|
From signing the informed consent until end of treatment, up to 991 days
|
Difference From Baseline for Bilirubin, Creatinine and Glucose
Tidsram: From signing the informed consent until end of treatment, up to 991 days
|
Difference from baseline (normalized value).
Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication.
The standard error is actually the Interquartile Range calculated as P75 minus P25.
|
From signing the informed consent until end of treatment, up to 991 days
|
Difference From Baseline for Haemoglobin
Tidsram: From baseline until end of treatment, up to 991 days
|
Difference from baseline for Haemoglobin (normalized value).
Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication.
The standard error is actually the Interquartile Range calculated as P75 minus P25.
|
From baseline until end of treatment, up to 991 days
|
Difference From Baseline for Haematology and Differentials Parameters
Tidsram: From signing the informed consent until end of treatment, up to 991 days
|
Difference from baseline (normalized value).
Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication.
The standard error is actually the Interquartile Range calculated as P75 minus P25.
|
From signing the informed consent until end of treatment, up to 991 days
|
Difference From Baseline for Coagulation Parameters
Tidsram: From signing the informed consent until end of treatment, up to 991 days
|
Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time.
Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication.
The standard error is actually the Interquartile Range calculated as P75 minus P25.
|
From signing the informed consent until end of treatment, up to 991 days
|
Difference From Baseline for Electrolytes
Tidsram: From signing the informed consent until end of treatment, up to 991 days
|
Difference from baseline (normalized value).
Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication.
The standard error is actually the Interquartile Range calculated as P75 minus P25.
|
From signing the informed consent until end of treatment, up to 991 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Clinically Relevant Abnormalities for Vital Signs
Tidsram: From baseline until final follow-up, up to 991 days
|
Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate).
New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
|
From baseline until final follow-up, up to 991 days
|
Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)
Tidsram: Just before drug administration every 28±7 days after day 29
|
Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29
|
Just before drug administration every 28±7 days after day 29
|
Unconfirmed Best Overall Response
Tidsram: Baseline until end of treatment, up to 991 days
|
Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0). PD = Progressive disease. |
Baseline until end of treatment, up to 991 days
|
Unconfirmed Best Objective Response
Tidsram: Baseline until end of treatment, up to 991 days
|
Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
|
Baseline until end of treatment, up to 991 days
|
Clinical Benefit
Tidsram: Baseline until end of treatment, up to 991 days
|
Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).
|
Baseline until end of treatment, up to 991 days
|
Confirmed Objective Response
Tidsram: Baseline until end of treatment, up to 991 days
|
Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
|
Baseline until end of treatment, up to 991 days
|
Progression Free Survival
Tidsram: First drug administration (in previous trial) until end of treatment, up to 1230 days
|
Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease. PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier. Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first. |
First drug administration (in previous trial) until end of treatment, up to 1230 days
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1199.16
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Neoplasmer
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMalign neoplasm | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | BRAF genmutationFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeTrötthet | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)AvslutadAvancerad malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Vårdgivare | Avancerad malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
Kliniska prövningar på BIBF 1120
-
Boehringer IngelheimAvslutadKarcinom, icke-småcellig lungaJapan
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)AvslutadÅterkommande livmoderkroppskarcinom | Endometriellt klart cell adenokarcinom | Endometriellt seröst adenokarcinom | Endometriellt odifferentierat karcinom | Endometrial Adenocarcinom | Endometrial övergångscellscancer | Endometriellt mucinöst adenokarcinom | Endometrial skivepitelcancer | Malignt uteruskorpus...Förenta staterna
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer IngelheimAvslutadÅterkommande icke-småcellig lungcancer | Steg IV Icke-småcellig lungcancer | Skivepitelcancer lungcancer | Steg III icke-småcellig lungcancerFörenta staterna
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AvslutadÅterkommande pleuramaligna mesoteliom | Steg IV Pleural MesoteliomFörenta staterna
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive...AvslutadÅterkommande kolonkarcinom | Återkommande rektalkarcinom | Rektal Adenocarcinom | Colon Adenocarcinom | Steg IVA tjocktarmscancer | Steg IVA ändtarmscancer | Steg IVB tjocktarmscancer | Steg IVB rektal cancerFörenta staterna
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkAvslutadKarcinoid tumör | Neuroendokrin neoplasma | Metastaserande karcinoidtumörFörenta staterna
-
Boehringer IngelheimAvslutadProstatiska neoplasmer
-
Boehringer IngelheimAvslutad
-
University College, LondonBoehringer IngelheimAvslutadÄggstockscancer | ÄggledarcancerStorbritannien